Some good news: Alzheimer's disease may be reversed
I like to keep these columns focused on information you can use today to make your tomorrows better. But every once in a while, there's a piece of research that offers such an exciting window on tomorrow's promise for a healthier future that I have to share it!
Researchers at Cleveland's Case Western Reserve University have found a way to restore fading levels of an essential bodily coenzyme called NAD+ (nicotinamide adenine dinucleotide) that helps convert food into cellular energy. When they do that for lab mice that are engineered to carry genetic mutations that cause Alzheimer's disease (AD), not only do the mice not develop AD, but those who have the disease see cognitive powers regained. While no NAD+ study has shown improvement in cognitive functioning in typical humans, this study opens the door to that next step.
When you combine that with the Cleveland Clinic's 20-year study of more than 20,000 folks designed to identify how to spot Alzheimer's before it causes symptoms, it looks like one day, not that far off, we may be able to eliminate the risk of Alzheimer's for many, many folks.
In the meantime, therapeutic plasma exchange has been shown to reverse cognitive dysfunction in early Alzheimer's (you can see all the research and the data on TPE's age-reversing powers at Lifespan-Edge.com). And even better, there are 30-plus ways to help prevent brain aging outlined in my book "The Great Age Reboot." If you don't try them, I have to ask: "What are you thinking?"
Health pioneer Michael Roizen, M.D., is chief wellness officer emeritus at the Cleveland Clinic and author of four No. 1 New York Times bestsellers. Check out his latest, "The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow," and find out more at www.4YOUngevity.com. Email your health and wellness questions to Dr. Mike at questions@4YOUngevity.com.
(c)2026 Michael Roizen, M.D.
Distributed by King Features Syndicate, Inc.
(c) 2026 Michael Roizen, M.D. Distributed by King Features Syndicate, Inc.























Comments